Structure-activity relationships for NAMI-A-type complexes (HL)[trans-RuCl4L(S-dmso)ruthenate(III)] (L = imidazole, indazole, 1,2,4-triazole, 4-amino-1,2,4-triazole, and 1-methyl-1,2,4-triazole):: Aquation, redox properties, protein binding, and antiproliferative activity

被引:211
作者
Groessl, Michael [1 ]
Reisner, Erwin [1 ]
Hartinger, Christian G. [1 ]
Eichinger, Rene [1 ]
Semenova, Olga [1 ]
Timerbaev, Andrei R. [1 ]
Jakupec, Michael A. [1 ]
Arion, Vladimir B. [1 ]
Keppler, Bernhard K. [1 ]
机构
[1] Univ Vienna, Inst Inorgan Chem, A-1090 Vienna, Austria
关键词
D O I
10.1021/jm061081y
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Imidazolium [trans-tetrachloro(1H-imidazole)(S-dimethylsulfoxide)ruthenate(III)] (NAMI-A) and indazolium [trans-tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019) are the most promising ruthenium complexes for anticancer chemotherapy. In this study, the azole ligand of NAMI-A was systematically varied (from imidazole of NAMI-A to indazole, 1,2,4-triazole, 4-amino-1,2,4-triazole, and 1-methyl-1,2,4-triazole), and the respective complexes were evaluated with regard to the rate of aquation and protein binding, redox potentials, and cytotoxicity by means of capillary zone electrophoresis, electrospray ionization mass spectrometry, cyclic voltammetry, and colorimetric microculture assays. Stability studies demonstrated low stability of the complexes at pH 7.4 and 37 degrees C and a high reactivity toward proteins (binding rate constants in the ranges of 0.02-0.34 and 0.01-0.26 min(-1) for albumin and transferrin, respectively). The redox potentials (between 0.25 and 0.35 V) were found to be biologically accessible for activation of the complexes in the tumor, and the indazole-containing compound shows the highest antiproliferative activity in vitro.
引用
收藏
页码:2185 / 2193
页数:9
相关论文
共 56 条
  • [2] Ruthenium antimetastatic agents
    Alessio, E
    Mestroni, G
    Bergamo, A
    Sava, G
    [J]. CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2004, 4 (15) : 1525 - 1535
  • [3] Classical and non-classical ruthenium-based anticancer drugs: Towards targeted chemotherapy
    Ang, Wee Han
    Dyson, Paul J.
    [J]. EUROPEAN JOURNAL OF INORGANIC CHEMISTRY, 2006, (20) : 4003 - 4018
  • [4] [Anonymous], [No title captured], Patent No. 9800431
  • [5] Synthesis, X-ray diffraction structures, spectroscopic properties, and in vitro antitumor activity of isomeric (1H-1,2+triazoIe)Ru(III) complexes
    Arion, VB
    Reisner, E
    Fremuth, M
    Jakupec, MA
    Keppler, BK
    Kukushkin, VY
    Pombeiro, AJL
    [J]. INORGANIC CHEMISTRY, 2003, 42 (19) : 6024 - 6031
  • [6] The hydrolysis of the anti-cancer ruthenium complex NAMI-A affects its DNA binding and antimetastatic activity: an NMR evaluation
    Bacac, M
    Hotze, ACG
    van der Schilden, K
    Haasnoot, JG
    Pacor, S
    Alessio, E
    Sava, G
    Reedijk, J
    [J]. JOURNAL OF INORGANIC BIOCHEMISTRY, 2004, 98 (02) : 402 - 412
  • [7] Bergamo A, 1999, J PHARMACOL EXP THER, V289, P559
  • [8] Bergamo A, 2001, ANTICANCER RES, V21, P1893
  • [9] Development of a LC method for pharmaceutical quality control of the antimetastatic ruthenium complex NAMI-A
    Bouma, M
    Nuijen, B
    Jansen, MT
    Sava, G
    Picotti, F
    Flaibani, A
    Bult, A
    Beijnen, JH
    [J]. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2003, 31 (02) : 215 - 228
  • [10] Photostability profiles of the experimental antimetastatic ruthenium complex NAMI-A
    Bouma, M
    Nuijen, B
    Jansen, MT
    Sava, G
    Bult, A
    Beijnen, JH
    [J]. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2002, 30 (04) : 1287 - 1296